Related Experiment Videos
Open trial of imipenem/cilastatin therapy for serious bacterial infections
Abstract:
Imipenem is a new beta-lactam antibiotic with a wide spectrum of activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The efficacy and toxicity of this drug, when administered parenterally in combination with the dehydropeptidase I inhibitor cilastatin, were studied in 41 hospitalized patients with serious infections. Clinical cure was achieved in 26 (79%) of the 33 patients who could be evaluated and microbiologic cure in 23 (85%) of the 27 patients who could be evaluated. Adverse clinical or laboratory reactions were observed in seven (17%) of the 41 patients. Thus, imipenem/cilastatin was highly effective in the treatment of a wide variety of serious bacterial infections.
Insights
The new antibiotic imipenem/cilastatin demonstrated high efficacy in treating serious bacterial infections. This combination therapy showed significant clinical and microbiologic cure rates with a favorable safety profile in hospitalized patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Imipenem is a novel beta-lactam antibiotic.
- It exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including anaerobes.
- Cilastatin is a dehydropeptidase I inhibitor used in combination with imipenem.
Purpose of the Study:
- To evaluate the efficacy and toxicity of parenteral imipenem/cilastatin.
- To assess treatment outcomes in hospitalized patients with serious infections.
Main Methods:
- A study involving 41 hospitalized patients with serious bacterial infections.
- Parenteral administration of imipenem in combination with cilastatin.
- Evaluation of clinical cure, microbiologic cure, and adverse reactions.
Main Results:
- Clinical cure was achieved in 79% (26/33) of evaluable patients.
- Microbiologic cure was observed in 85% (23/27) of evaluable patients.
- Adverse reactions occurred in 17% (7/41) of patients.
Conclusions:
- Imipenem/cilastatin is highly effective for treating diverse serious bacterial infections.
- The combination therapy demonstrated a good safety profile.
- Parenteral imipenem/cilastatin represents a valuable therapeutic option for severe infections.